US20140242028A1 - Antiviral compounds - Google Patents

Antiviral compounds Download PDF

Info

Publication number
US20140242028A1
US20140242028A1 US14/159,566 US201414159566A US2014242028A1 US 20140242028 A1 US20140242028 A1 US 20140242028A1 US 201414159566 A US201414159566 A US 201414159566A US 2014242028 A1 US2014242028 A1 US 2014242028A1
Authority
US
United States
Prior art keywords
compound
phenyl
hcv
triazole
diamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/159,566
Other languages
English (en)
Inventor
Joseph Anthony Bilotta
Zhi Chen
Qingjie Ding
Shawn David Erickson
Eric Mertz
Robert James Weikert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Hoffmann La Roche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche Inc filed Critical Hoffmann La Roche Inc
Priority to US14/159,566 priority Critical patent/US20140242028A1/en
Assigned to HOFFMANN-LA ROCHE INC. reassignment HOFFMANN-LA ROCHE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DING, QINGJIE, ERICKSON, SHAWN D., MERTZ, ERIC, BILOTTA, JOSEPH A., CHEN, ZHI, WEIKERT, ROBERT JAMES
Assigned to F. HOFFMANN-LA ROCHE AG reassignment F. HOFFMANN-LA ROCHE AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HOFFMANN-LA ROCHE INC.
Publication of US20140242028A1 publication Critical patent/US20140242028A1/en
Priority to US14/827,762 priority patent/US9511059B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
US14/159,566 2013-01-23 2014-01-21 Antiviral compounds Abandoned US20140242028A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/159,566 US20140242028A1 (en) 2013-01-23 2014-01-21 Antiviral compounds
US14/827,762 US9511059B2 (en) 2013-01-23 2015-08-17 Antiviral compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361755519P 2013-01-23 2013-01-23
US14/159,566 US20140242028A1 (en) 2013-01-23 2014-01-21 Antiviral compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/827,762 Continuation US9511059B2 (en) 2013-01-23 2015-08-17 Antiviral compounds

Publications (1)

Publication Number Publication Date
US20140242028A1 true US20140242028A1 (en) 2014-08-28

Family

ID=50033474

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/159,566 Abandoned US20140242028A1 (en) 2013-01-23 2014-01-21 Antiviral compounds
US14/827,762 Expired - Fee Related US9511059B2 (en) 2013-01-23 2015-08-17 Antiviral compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/827,762 Expired - Fee Related US9511059B2 (en) 2013-01-23 2015-08-17 Antiviral compounds

Country Status (11)

Country Link
US (2) US20140242028A1 (fr)
EP (1) EP2948440B1 (fr)
JP (1) JP6096324B2 (fr)
KR (1) KR20150109451A (fr)
CN (1) CN105073726B (fr)
BR (1) BR112015017414A2 (fr)
CA (1) CA2892589A1 (fr)
HK (1) HK1217694A1 (fr)
MX (1) MX2015009176A (fr)
RU (1) RU2015132550A (fr)
WO (1) WO2014114573A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014135423A1 (fr) * 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Dérivés d'aniline à substitution n-hétéoaryle comme anti-vhc
CN106467501B (zh) * 2015-08-18 2018-10-26 中国医学科学院医药生物技术研究所 新型抗病毒化合物
MX2019004293A (es) * 2016-10-14 2019-10-14 Pi Industries Ltd Derivados de fenilamina sustituidos en la posicion 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatogenos no deseados.
CN115703726B (zh) * 2021-08-08 2024-04-02 上海泰初化工技术有限公司 一种三氟甲基苯硫醚化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
SE508697C2 (sv) 1996-07-19 1998-10-26 Ericsson Telefon Ab L M Förfarande och anordning för tidskontinuerlig filtrering i digital CMOS-process
BR9712544B1 (pt) 1996-10-18 2013-10-22 Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
EP1012180B1 (fr) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Analogues de peptides inhibiteurs de l'hepatite c
WO2000006529A1 (fr) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Derives de dicetoacides utilises comme inhibiteurs de polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
KR20010099623A (ko) 1998-08-21 2001-11-09 비로파마 인코포레이티드 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법
BR9913406A (pt) 1998-09-04 2002-01-29 Viropharma Inc Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
EP1115286A4 (fr) 1998-09-25 2003-07-23 Viropharma Inc Procedes de traitement ou de prevention d'infections virales et de maladies associees
EE200100492A (et) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated Ensüümi IMPDH inhibiitorid
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
AU2001261377A1 (en) 2000-05-10 2001-11-20 Smith Kline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
WO2002100846A1 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
PL208713B1 (pl) 2001-06-11 2011-05-31 Virochem Pharma Inc Związek stanowiący pochodną tiofenu, kompozycja farmaceutyczna zawierająca taki związek i jego zastosowanie
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
WO2003037895A1 (fr) 2001-11-02 2003-05-08 Glaxo Group Limited Derives d'heteroaryl acyl pyrrolidine a 4 a 6 chainons utilises comme inhibiteurs de hcv
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
AR048401A1 (es) 2004-01-30 2006-04-26 Medivir Ab Inhibidores de la serina-proteasa ns3 del vhc
CA2621503C (fr) * 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Derives de triazole utiles comme inhibiteurs d'axl
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140010783A1 (en) * 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds

Also Published As

Publication number Publication date
CN105073726A (zh) 2015-11-18
CN105073726B (zh) 2017-05-31
RU2015132550A (ru) 2017-03-02
BR112015017414A2 (pt) 2017-07-11
JP2016505056A (ja) 2016-02-18
JP6096324B2 (ja) 2017-03-15
US20150353511A1 (en) 2015-12-10
WO2014114573A1 (fr) 2014-07-31
EP2948440A1 (fr) 2015-12-02
HK1217694A1 (zh) 2017-01-20
CA2892589A1 (fr) 2014-07-31
EP2948440B1 (fr) 2017-04-12
KR20150109451A (ko) 2015-10-01
US9511059B2 (en) 2016-12-06
MX2015009176A (es) 2015-11-09

Similar Documents

Publication Publication Date Title
US9428469B2 (en) Antiviral compounds
EP2870143B1 (fr) Composés triazoliques comme antiviraux
US9693997B2 (en) Antiviral compounds
US9511059B2 (en) Antiviral compounds
US9382218B2 (en) N-heteroaryl substituted aniline derivatives as HCV-antivirals
US20160002180A1 (en) Antiviral compounds
US9896433B2 (en) Antiviral compounds
US9540345B2 (en) Antiviral compounds

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BILOTTA, JOSEPH A.;CHEN, ZHI;DING, QINGJIE;AND OTHERS;SIGNING DATES FROM 20130124 TO 20130131;REEL/FRAME:032836/0860

Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HOFFMANN-LA ROCHE INC.;REEL/FRAME:032836/0932

Effective date: 20130213

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION